Here is the summary in YAML format:

**Case Information**

* Case Number: 21STCV02371
* Hearing Date: October 2, 2023
* Department: 39
* Plaintiff: Brink Biologics, Inc.
* Defendants: Sanofi, S.A., Sanofi-Aventis U.S., LLC, Sanofi-Aventis Recherche & Developpement, S.A.

**People and Entities**

* Anlai Wang
* Matthew Blackburn
* Leeanne S. Mancari
* Francisco Adrian
* David Dube
* Ronan Crepin
* Romain Pizzato
* Alain Fouriner
* Dominique Brault
* Nicholas McCray
* Conkwest Incorporated
* Sanofi
* Sanofi-Aventis U.S., LLC
* Sanofi-Aventis Recherche & Developpement, S.A.
* Brink Biologics, Inc.

**Places**

* France
* Framingham, Massachusetts

**Dates**

* December 16, 2011
* January 19, 2021
* August 1, 2022
* July 18, 2023
* September 11, 2023
* September 26, 2023

**Events**

* License agreement between Conkwest and Sanofi-Aventis Recherche & Developpement, S.A.
* Termination of license agreement by Brink Biologics, Inc.
* Cross-complaint filed by Sanofi
* Discovery disputes between parties
* Hearings on motions to compel further discovery responses
* Depositions of witnesses

**Money**

* None mentioned

**Intentions**

* Brink Biologics, Inc. seeks to compel compliance with the Court's order and to obtain discovery sanctions
* Sanofi seeks to defend against Brink Biologics, Inc.'s claims and to avoid discovery sanctions

**Facts**

* Brink Biologics, Inc. alleges that Sanofi modified the NK-92 cells and used them for commercial purposes
* Sanofi claims that the modifications were unsuccessful and that the cells were only used for research and development purposes
* Anlai Wang testified about her work with the NK-92 cells and the existence of paper notebooks

**Disputes**

* Brink Biologics, Inc. disputes Sanofi's claims about the use of the NK-92 cells
* Sanofi disputes Brink Biologics, Inc.'s claims about the modifications to the NK-92 cells

**Acts**

* Brink Biologics, Inc. filed a complaint against Sanofi
* Sanofi filed a cross-complaint against Brink Biologics, Inc.
* The parties engaged in discovery disputes
* Depositions were taken

**Agreements**

* License agreement between Conkwest and Sanofi-Aventis Recherche & Developpement, S.A.

**Laws**

* California Code of Civil Procedure
* Federal Rules of Civil Procedure

**Case Citations**

* None mentioned

**Statutes**

* California Code of Civil Procedure section 1209(a)(5)
* California Code of Civil Procedure section 2023.030

**Roles**

* Judge: The judge is the neutral third-party decision-maker in the case.
* Plaintiff: Brink Biologics, Inc. is the party bringing the lawsuit.
* Defendant: Sanofi, S.A., Sanofi-Aventis U.S., LLC, Sanofi-Aventis Recherche & Developpement, S.A. are the parties being sued.
* Counsel: Counsel refers